We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Extended Indications for Surgical Sealant

By HospiMedica staff writers
Posted on 13 Jun 2005
Following the publication of new fibrin sealant guidelines in January 2005, a human surgical sealant is now approved for use in improving hemostasis, where standard surgical techniques are insufficient.

Called Quixil, the sealant was previously only indicated for liver surgery and large-joint replacement where efficacy has been proven. More...
In traditional fibrin sealants, bovine sourced proteins are present. Quixil, however, is the only sealant that is completely free of animal-sourced components. The sealant is ready for application in less than one minute after thawing and is more adherent and flexible than traditional fibrin sealants, even at low temperatures, potentially lowering sepsis rates.

The two-component sealant consists of a biologic active component (BAC)--human clottable protein and tranexamic acid--and thrombin. Each of the components undergoes two separate and different virus activation and removal steps during manufacturing to reduce the risk of transmission of non-enveloped viruses. This also increases the probability of inactivating unidentified pathogens.

Quixil is a registered trademark of Omrix Biopharmaceuticals, S.A. (Brussels, Belgium) and is marketed in the United Kingdom by Johnson & Johnson Wound Management (New Brunswick, NJ, USA).






Related Links:
Johnson & Johnson

Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Isolation Stretcher
IS 736
OR Table Accessory
Angular Accessory Rail
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.